Education
About Us
Working with TipRanks
Follow Us
Immuno-Biological Laboratories Co., Ltd. (JP:4570)
:4570
4570 Stock Chart & Stats
¥1613.00
¥18.00(3.96%)
At close: 4:00 PM EST
¥1613.00
¥18.00(3.96%)
Day’s Range― - ―
52-Week Range¥356.00 - ¥3,820.00
Previous CloseN/A
Volume75.00K
Average Volume (3M)23.51K
Market Cap
¥13.46B
Enterprise Value¥3.94B
Total Cash (Recent Filing)¥903.75M
Total Debt (Recent Filing)¥196.94M
Price to Earnings (P/E)40.2
Beta1.01
Next Earnings
Feb 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.67
Shares Outstanding9,314,590
10 Day Avg. Volume28,690
30 Day Avg. Volume23,506
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)2.95
Price to Sales (P/S)4.61
P/FCF Ratio36.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
4570 FAQ
What was Immuno-Biological Laboratories Co., Ltd.’s price range in the past 12 months?
Immuno-Biological Laboratories Co., Ltd. lowest stock price was ¥356.00 and its highest was ¥3820.00 in the past 12 months.
What is Immuno-Biological Laboratories Co., Ltd.’s market cap?
Immuno-Biological Laboratories Co., Ltd.’s market cap is ¥13.46B.
When is Immuno-Biological Laboratories Co., Ltd.’s upcoming earnings report date?
Immuno-Biological Laboratories Co., Ltd.’s upcoming earnings report date is Feb 06, 2026 which is in 49 days.
How were Immuno-Biological Laboratories Co., Ltd.’s earnings last quarter?
Immuno-Biological Laboratories Co., Ltd. released its earnings results on Nov 13, 2025. The company reported ¥8.67 earnings per share for the quarter, beating the consensus estimate of N/A by ¥8.67.
Is Immuno-Biological Laboratories Co., Ltd. overvalued?
According to Wall Street analysts Immuno-Biological Laboratories Co., Ltd.’s price is currently Overvalued.
Does Immuno-Biological Laboratories Co., Ltd. pay dividends?
Immuno-Biological Laboratories Co., Ltd. pays a Notavailable dividend of ¥6 which represents an annual dividend yield of N/A. See more information on Immuno-Biological Laboratories Co., Ltd. dividends here
What is Immuno-Biological Laboratories Co., Ltd.’s EPS estimate?
Immuno-Biological Laboratories Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immuno-Biological Laboratories Co., Ltd. have?
Immuno-Biological Laboratories Co., Ltd. has 9,314,590 shares outstanding.
What happened to Immuno-Biological Laboratories Co., Ltd.’s price movement after its last earnings report?
Immuno-Biological Laboratories Co., Ltd. reported an EPS of ¥8.67 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 12.97%.
Which hedge fund is a major shareholder of Immuno-Biological Laboratories Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4570
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Immuno-Biological Laboratories Co., Ltd.
Immuno-Biological Laboratories Co., Ltd. (4570) is a biotechnology company based in Japan, specializing in the development and manufacture of immunological diagnostic products and reagents. The company operates primarily in the healthcare sector, focusing on providing innovative solutions for disease diagnosis and treatment monitoring. Key products include various types of immunoassays, including those for infectious diseases, allergies, and autoimmune disorders, catering to both clinical laboratories and research institutions.
Technical Analysis
Ribomic, Inc.
―
BrightPath Biotherapeutics Co.Ltd.
―
Delta-Fly Pharma, Inc.
―
FunPep Company Limited
―
Kringle Pharma, Inc.
―